Suppr超能文献

人胎儿及成人下丘脑促肾上腺皮质激素释放因子样免疫反应性和生物活性

Corticotrophin-releasing factor-like immunoreactivity and bioactivity of human fetal and adult hypothalami.

作者信息

Ackland J F, Ratter S J, Bourne G L, Rees L H

出版信息

J Endocrinol. 1986 Feb;108(2):171-80. doi: 10.1677/joe.0.1080171.

Abstract

Corticotrophin releasing factor-like immunoreactivity (CRF-LI) and bioactivity, and arginine vasopressin-like immunoreactivity (AVP-LI) have been measured in extracts of human fetal and adult hypothalamic tissue and their development with the gestational age of the fetuses (12-27 weeks) studied. CRF-LI was measured by a radioimmunoassay developed for ovine corticotrophin-releasing factor (oCRF-41). Corticotrophin-releasing factor bioactivity was measured in a rat isolated anterior pituitary cell perfusion system. CRF-LI and bioactivity and AVP-LI were all detectable in fetal hypothalamic extracts from 12 to 13 weeks of gestational age. CRF-LI was also present in human fetal pituitary glands from 12 weeks of gestational age. The concentration of CRF-LI in the fetal hypothalamic extracts (9.2 +/- 11.4 ng/g, mean +/- S.E.M., n = 33) showed no significant correlation with the gestational age of the fetuses. However the concentration of AVP-LI (25.0-36.8 ng/g, n = 17) did show a positive correlation (r = 0.508, P less than 0.05) with gestational age, as did the concentration of CRF bioactivity (471.3-556.3 ng ACTH released/g tissue, n = 13, r = 0.725, P less than 0.01). The CRF bioactivity of all fetal hypothalamic extracts was potentiated by the addition of synthetic human (h)AVP, but the bioactivity of the adult hypothalamic extracts was not, presumably because of the higher levels of AVP-LI already present in the adult extracts. Pretreatment of tissue extracts with antisera to oCRF-41 and/or hAVP reduced the CRF bioactivity of all hypothalamic extracts. Sephadex chromatography of fractions which co-eluted with synthetic oCRF-41 or hAVP contained CRF bioactivity and this bioactivity was potentiated when synthetic hAVP or oCRF-41, respectively, were added to the fractions. However, a larger molecular weight form of CRF-LI (8000-10 000 daltons), which was observed only in fetuses of 20 weeks of gestational age or less, did not contain any significant CRF bioactivity.

摘要

已对人胎儿和成人下丘脑组织提取物中的促肾上腺皮质激素释放因子样免疫反应性(CRF-LI)和生物活性以及精氨酸加压素样免疫反应性(AVP-LI)进行了测量,并研究了它们随胎儿胎龄(12至27周)的发育情况。CRF-LI通过针对绵羊促肾上腺皮质激素释放因子(oCRF-41)开发的放射免疫测定法进行测量。促肾上腺皮质激素释放因子生物活性在大鼠离体垂体前叶细胞灌注系统中进行测量。在胎龄12至13周的胎儿下丘脑提取物中均可检测到CRF-LI、生物活性和AVP-LI。胎龄12周起,人胎儿垂体中也存在CRF-LI。胎儿下丘脑提取物中CRF-LI的浓度(9.2±11.4 ng/g,平均值±标准误,n = 33)与胎儿胎龄无显著相关性。然而,AVP-LI的浓度(25.0 - 36.8 ng/g,n = 17)与胎龄呈正相关(r = 0.508,P < 0.05),CRF生物活性的浓度(471.3 - 556.3 ng促肾上腺皮质激素释放/g组织,n = 13,r = 0.725,P < 0.01)也是如此。添加合成人(h)AVP可增强所有胎儿下丘脑提取物的CRF生物活性,但成人下丘脑提取物的生物活性则不然,推测是因为成人提取物中已存在较高水平的AVP-LI。用抗oCRF-41和/或hAVP抗血清对组织提取物进行预处理可降低所有下丘脑提取物的CRF生物活性。与合成oCRF-41或hAVP共洗脱的级分经葡聚糖凝胶色谱分析含有CRF生物活性,当分别向这些级分中添加合成hAVP或oCRF-41时,该生物活性会增强。然而,仅在胎龄20周及以下胎儿中观察到的分子量较大的CRF-LI形式(8000 - 10000道尔顿)不含有任何显著的CRF生物活性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验